Integrating clinical and laboratory parameters with PBII, particularly PIV, may be a valuable, noninvasive tool for the early detection and risk stratification of endometrial malignancies. This approach could enhance diagnostic accuracy, reduce the need for invasive biopsies, and improve patient management.
Altınsoy et al. (Sun,) studied this question.